<?xml version="1.0" encoding="UTF-8"?>
<p id="Par86">The newly emergent Middle East respiratory syndrome coronavirus (MERS-CoV) induces a severe acute respiratory syndrome-like disease with an approximately 43% mortality rate [
 <xref ref-type="bibr" rid="CR134">134</xref>]. To date, no vaccines or antiviral medications are available for the prevention or clinical treatment of MERS. A large phage-displayed human naive scFv library (Mehta I/II) with 2.7 × 10
 <sup>10</sup> clones from the Dana-Farber Cancer Institute was used as a resource for the isolation of human antibodies against MERS-CoV [
 <xref ref-type="bibr" rid="CR135">135</xref>]. In another project, a research group in Malaysia improved panning strategies with a naïve human scFv library (library size of 10
 <sup>9</sup>) to successfully identify mAbs specific to the MERS-CoV nucleoprotein [
 <xref ref-type="bibr" rid="CR136">136</xref>].
</p>
